Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum J26 is a probiotic bacterial strain isolated from Chinese traditional fermented dairy products. It exhibits significant immunomodulatory activity by regulating the expression of immune-related genes, including upregulation of cytokines such as IL-1α, IL-1β, IL-6, and TNF-α in the intestinal tract. The strain produces teichoic acids that are key molecules involved in modulating host immune responses[1]. L. plantarum J26 has demonstrated beneficial effects in animal models for alleviating alcohol-induced liver injury by reducing Gram-negative pathogenic bacteria abundance, maintaining intestinal barrier integrity, and inhibiting TLR4-mediated MAPK signaling to reduce liver inflammation[5][6]. Additionally, postbiotics derived from this strain (J26P) have shown efficacy in lowering cholesterol and improving metabolic parameters via regulation of the LXRα–CYP7A1–bile acid excretion pathway in hypercholesterolemic mice[7]. Its mechanisms also include increasing short-chain fatty acid production and activating Nrf2 signaling to alleviate oxidative stress[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus plantarum J26.